MedPath

Metastatix, Inc.

🇺🇸United States
Ownership
Private, Subsidiary
Employees
-
Market Cap
-
Website
http://www.metastatix.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Phase 1
Suspended
Conditions
Solid Tumors
Interventions
First Posted Date
2008-01-11
Last Posted Date
2008-03-26
Lead Sponsor
Metastatix, Inc.
Target Recruit Count
27
Registration Number
NCT00591682
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.